Skip to content

Use of Perioperative Pain Blocks In Urological Surgery

Use of Perioperative Pain Blocks In Urological Surgery: A Phase III Randomized Single Blind Single Center Three Arm Non-inferiority Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04426500
Enrollment
148
Registered
2020-06-11
Start date
2019-11-11
Completion date
2021-02-13
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve Block, Pain, Postoperative, Robotic Surgical Procedures

Keywords

Phase III, Randomized, Single blind, Single Center, Three arm, Non-inferiority

Brief summary

The study team aims to prospectively compare Placebo (local administration), ultrasound-guided transversus abdominis plane (UTAP) blocks, and laparoscopic-guided transversus abdominis plane (LTAP) blocks in patients undergoing robotic surgery of the prostate and kidney. The study team expects to be able to equally efficiently administer the blocks using direct visualization and ultrasound guidance. The study team expects that a negative result would obviate the need for longer operative time by eliminating the need for the separate ultrasound guided block while a positive result would demonstrate the increased utility of preoperative ultrasound blocks in managing postoperative pain.

Detailed description

Currently, ultrasound-guided transversus abdominis plane (UTAP) blocks (regional anesthetic blocks) are being employed for the care of urological surgery patients. Local and regional anesthesia is commonly used throughout surgical fields. However, ultrasound-guidance can be challenging, particularly in larger, obese patients. It is unknown how such techniques compare to laparoscopic-guided blockade, with respect to time to perform, learning curve, and postoperative analgesia. The transversus abdominis plane lies deep within the abdominal wall, potentially allowing for greater ease of access from a laparoscopic approach from within than the ultrasound guided percutaneous approach. Prior randomized studies have been completed comparing UTAP and Placebo. In 2012 Hosgood et al. compared UTAP and placebo (UTAP w/ saline) in 46 live-donor laparoscopic nephrectomy patients (24 UTAP vs. 22 placebo). Pain control (measured using the 0-10 VAS scale) was greater on post-operative day (POD) 1 in patients receiving UTAP than in controls, 19 (15) vs. 37 (20) (presented as mean (SD)), respectively. A similar randomized study in 2014 compared UTAP and placebo (UTAP w/saline) in 21 hand assisted laparoscopic nephrectomy patients (10 UTAP vs. 11 placebo). The study was initially powered for 50 patients but with decreased accrual secondary to a surgeon taking a leave of absence during the study period. Pain scores were recorded using the 0-10 VAS score. Postoperatively at 24 hours (median (IQR)) UTAP patients demonstrated decreased postoperative pain than placebo patients (1 (0-2) vs. 4 (2-6)) on the VAS score, respectively. A larger study, done in 2016, with 80 randomized patients undergoing retroperitoneal laparoscopic urologic surgery compared UTAP (40) and saline UTAP (40). Pain scores were assessed using the 0-100 VAS score scale. On POD1, UTAP group had lower pain scores (mean (SD)) of 8.4 (5.9) vs. placebo 28.3 (12.2). The most recent study, done in 2018, examined 100 randomized patients undergoing robotic-assisted laparoscopic prostatectomies. Fifty patients were given UTAP blocks while the others received no block. A Numerical Rating Scale (assumed to range from 0-10 as not otherwise specified) was used to assess pain. Patients receiving the block at 24 hours had better pain control (mean (SD)) (1.8 (0.82) vs. 3.57 (0.64)). While all of these studies point to potential efficacy of UTAP, no data has been published to date comparing laparoscopic administration of the TAP block (LTAP) to ultrasound guided administration. While these regional anesthetic blocks carry a theoretical risk of hematoma or damage to surrounding structures, none of the above studies report any complications with the injections. The study team aims to prospectively compare Placebo (local administration), UTAP, and LTAP blocks in patients undergoing robotic surgery of the prostate and kidney. The study team expects to be able to equally efficiently administer the blocks using direct visualization and ultrasound guidance. The study team expects that a negative result would obviate the need for longer operative time by eliminating the need for the separate ultrasound guided block while a positive result would demonstrate the increased utility of preoperative ultrasound blocks in managing postoperative pain.

Interventions

DRUGBupivacain

Direct injection of 0.25% bupivacaine into surgical wounds

bilateral TAP using ultrasound guidance in prostatectomies

DRUGLaparoscopic-guided transversus abdominus plane block

bilateral TAP using laparoscopic guidance in prostatectomies

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Masking description

A randomization service called Sealedenvelope.com available at https://www.sealedenvelope.com/simple-randomiser/v1/ will be used for allocation concealment to ensure that retrieval of the treatment group assignment is only revealed to appropriate team members on a real time basis after each new patient has been screened and consented. This service allows for allocation concealment that would not be possible if the entire randomization list was made available to team members at the beginning of the study. The security and integrity of the codes used by Sealedenvelope.com follows the Food and Drug Administration (FDA) standards for electronic records and follows the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines. Participants will be blinded to group allocation throughout the study. Due to the nature of the intervention, it is not possible to blind the investigator to group allocation.

Intervention model description

This is a single-center, single-blinded, (stratified) randomized placebo-controlled three-arm non-inferiority trial with 2:2:1 allocation ratio. People who meet eligibility requirements and provide informed consent will be randomly allocated to 3 groups to receive either UTAP, LTAP or Placebo with a 2:2:1 allocation ratio. The allocation sequence will be stratified by type of surgery (prostatectomy or partial nephrectomy) using stratified block randomization with randomly varying block sizes. Random permuted blocks sizes within stratification groups will be used to minimize the chance of selection bias. Investigators will be blinded to the size of each block with only the study statistician responsible for generating the randomization list knowing this information.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Undergoing Robotic Assisted Laparoscopic Partial Nephrectomy or Robotic Assisted Laparoscopic Prostatectomy * Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

* Prior Partial Nephrectomy or Subtotal Prostatectomy Surgery (organ specific) * Conversion to open surgery * History of chronic pain * History of opiate or alcohol dependence * Allergies to local anesthetic * Retroperitoneal surgery * Single Port Surgery

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale (VAS)24 hours post operativelyVisual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain

Secondary

MeasureTime frameDescription
Intraoperative Narcotic Useup to 420 minutesIntraoperative Narcotic Use in morphine equivalents
Intraoperative Ketoralac Useup to 420 minutesIntraoperative Ketoralac Use
Postoperative Narcotic Use24 hours post operativelyPostoperative Narcotic Use in morphine equivalents
Total Analgesic Medications24 hours post operativelyThe 24-hour cumulative postoperative opioid analgesic requirement was calculated using standard tables to morphine equivalents.
Intraoperative Time and Block Timeup to 420 minutesIntraoperative time taken to complete surgical blocks and operative
Number of Days to Return of Bowel Function2 weeksNumber of days to the return of bowel function
The Length of Hospital Stay2 weeksLength of hospital stay from time of surgical completion to time of discharge.
VAS in Obese Patients24 hours post operatively24 hour postoperative pain scores recorded using the visual analog scale (VAS) in obese patients. Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain. Comparison in patients with BMI \>30 and BMI\<30
Number of Procedure Related Complications2 weeksProcedure related complications and adverse events including bleeding or injection of anesthetic intravascular was determined according to Common Terminology Criteria for Adverse Events (CTCAE v 4.0).
The Amount of Ondansetron Use2 weeksUse of antiemetic medications during the postoperative course

Countries

United States

Participant flow

Recruitment details

196 patients were eligible for the study and initially randomized. A total of 143 prostatectomy patients were deemed appropriate candidates for the trial and randomized and 114 participants were then enrolled. A total of 53 partial nephrectomy patients were deemed appropriate candidates for the trial. 34 participants were randomized and then enrolled.

Participants by arm

ArmCount
Robotic -Guided Transversus Abdominus Plane (RTAP) Block
30mL of 0.25% bupivacaine injected bilaterally in the TAP plane using a RTAP through the assistant port with a laparoscopic needle driver guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting). Bupivacain: Direct injection of 0.25% bupivacaine into surgical wounds Laparoscopic-guided transversus abdominus plane block: bilateral TAP using laparoscopic guidance in prostatectomies
56
Ultrasound-guided Transversus Abdominus Plane (UTAP) Block
30mL of 0.25% bupivacaine administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% aliquot bupivacaine unilateral administered in nephrectomy patients (weight based dosage permitting). Bupivacain: Direct injection of 0.25% bupivacaine into surgical wounds Ultrasound-guided transversus abdominus plane block: bilateral TAP using ultrasound guidance in prostatectomies
64
Placebo/Local Anesthesia
Up to 60ml of 0.25% bupivacaine was injected directly into each of the port sites and specimen extraction site at the conclusion of the procedure prior to skin closure.
28
Total148

Baseline characteristics

CharacteristicRobotic -Guided Transversus Abdominus Plane (RTAP) BlockUltrasound-guided Transversus Abdominus Plane (UTAP) BlockPlacebo/Local AnesthesiaTotal
Age, Continuous62.1 years
STANDARD_DEVIATION 9.5
63.0 years
STANDARD_DEVIATION 10.6
63.7 years
STANDARD_DEVIATION 6.6
62.8 years
STANDARD_DEVIATION 9.5
Body Mass Index (BMI)27.0 Kg/m^2
STANDARD_DEVIATION 4.14
28.6 Kg/m^2
STANDARD_DEVIATION 4.9
26.6 Kg/m^2
STANDARD_DEVIATION 4.25
27.5 Kg/m^2
STANDARD_DEVIATION 4.6
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
4 Participants4 Participants1 Participants9 Participants
Sex: Female, Male
Male
52 Participants60 Participants27 Participants139 Participants
Surgical Procedure
Robotic Partial Nephrectomy (RPN)
13 Participants13 Participants8 Participants34 Participants
Surgical Procedure
Robotic Prostatectomy (RP)
43 Participants51 Participants20 Participants114 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 280 / 640 / 56
other
Total, other adverse events
0 / 280 / 640 / 56
serious
Total, serious adverse events
0 / 280 / 640 / 56

Outcome results

Primary

Visual Analog Scale (VAS)

Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain

Time frame: 24 hours post operatively

ArmMeasureValue (MEAN)Dispersion
Placebo/Local AnesthesiaVisual Analog Scale (VAS)1.29 score on a scaleStandard Deviation 1.98
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockVisual Analog Scale (VAS)3.16 score on a scaleStandard Deviation 3.1
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockVisual Analog Scale (VAS)2.89 score on a scaleStandard Deviation 2.69
Secondary

Intraoperative Ketoralac Use

Intraoperative Ketoralac Use

Time frame: up to 420 minutes

ArmMeasureValue (MEDIAN)
Placebo/Local AnesthesiaIntraoperative Ketoralac Use0 mg
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockIntraoperative Ketoralac Use0 mg
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockIntraoperative Ketoralac Use15 mg
Secondary

Intraoperative Narcotic Use

Intraoperative Narcotic Use in morphine equivalents

Time frame: up to 420 minutes

ArmMeasureValue (MEAN)Dispersion
Placebo/Local AnesthesiaIntraoperative Narcotic Use27.0 morphine equivalentsStandard Deviation 12.6
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockIntraoperative Narcotic Use24.1 morphine equivalentsStandard Deviation 12.64
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockIntraoperative Narcotic Use25.5 morphine equivalentsStandard Deviation 15.2
Secondary

Intraoperative Time and Block Time

Intraoperative time taken to complete surgical blocks and operative

Time frame: up to 420 minutes

ArmMeasureGroupValue (MEDIAN)
Placebo/Local AnesthesiaIntraoperative Time and Block TimeTime Taken to Perform Block2.5 minutes
Placebo/Local AnesthesiaIntraoperative Time and Block TimeTotal OR Time211.5 minutes
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockIntraoperative Time and Block TimeTime Taken to Perform Block6.0 minutes
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockIntraoperative Time and Block TimeTotal OR Time224.5 minutes
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockIntraoperative Time and Block TimeTime Taken to Perform Block2.5 minutes
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockIntraoperative Time and Block TimeTotal OR Time221 minutes
Secondary

Number of Days to Return of Bowel Function

Number of days to the return of bowel function

Time frame: 2 weeks

Population: Data not collected.

Secondary

Number of Procedure Related Complications

Procedure related complications and adverse events including bleeding or injection of anesthetic intravascular was determined according to Common Terminology Criteria for Adverse Events (CTCAE v 4.0).

Time frame: 2 weeks

ArmMeasureValue (NUMBER)
Placebo/Local AnesthesiaNumber of Procedure Related Complications0 events
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockNumber of Procedure Related Complications0 events
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockNumber of Procedure Related Complications0 events
Secondary

Postoperative Narcotic Use

Postoperative Narcotic Use in morphine equivalents

Time frame: 24 hours post operatively

ArmMeasureValue (MEDIAN)
Placebo/Local AnesthesiaPostoperative Narcotic Use14.13 morphine equivalents
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockPostoperative Narcotic Use19.50 morphine equivalents
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockPostoperative Narcotic Use17 morphine equivalents
Secondary

The Amount of Ondansetron Use

Use of antiemetic medications during the postoperative course

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Placebo/Local AnesthesiaThe Amount of Ondansetron Use0.05 mgStandard Deviation 0.19
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockThe Amount of Ondansetron Use0.31 mgStandard Deviation 1.3
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockThe Amount of Ondansetron Use0.29 mgStandard Deviation 1.29
Secondary

The Length of Hospital Stay

Length of hospital stay from time of surgical completion to time of discharge.

Time frame: 2 weeks

Population: Data not collected.

Secondary

Total Analgesic Medications

The 24-hour cumulative postoperative opioid analgesic requirement was calculated using standard tables to morphine equivalents.

Time frame: 24 hours post operatively

ArmMeasureGroupValue (MEDIAN)
Placebo/Local AnesthesiaTotal Analgesic MedicationsAcetaminophen1650 mg morphine equivalents
Placebo/Local AnesthesiaTotal Analgesic MedicationsKetorlac0 mg morphine equivalents
Placebo/Local AnesthesiaTotal Analgesic MedicationsOndansetron0 mg morphine equivalents
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockTotal Analgesic MedicationsAcetaminophen1650 mg morphine equivalents
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockTotal Analgesic MedicationsKetorlac30 mg morphine equivalents
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockTotal Analgesic MedicationsOndansetron0 mg morphine equivalents
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockTotal Analgesic MedicationsKetorlac0 mg morphine equivalents
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockTotal Analgesic MedicationsOndansetron0 mg morphine equivalents
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockTotal Analgesic MedicationsAcetaminophen1325 mg morphine equivalents
Secondary

VAS in Obese Patients

24 hour postoperative pain scores recorded using the visual analog scale (VAS) in obese patients. Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain. Comparison in patients with BMI \>30 and BMI\<30

Time frame: 24 hours post operatively

Population: participants divided by BMI \>30 and BMI \<30

ArmMeasureGroupValue (MEAN)Dispersion
Placebo/Local AnesthesiaVAS in Obese PatientsBMI >301.29 score on a scaleStandard Deviation 2.21
Placebo/Local AnesthesiaVAS in Obese PatientsBMI <301.29 score on a scaleStandard Deviation 1.95
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockVAS in Obese PatientsBMI >304.09 score on a scaleStandard Deviation 2.94
Ultrasound-guided Transversus Abdominus Plane (UTAP) BlockVAS in Obese PatientsBMI <302.67 score on a scaleStandard Deviation 3.11
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockVAS in Obese PatientsBMI >302.33 score on a scaleStandard Deviation 2.24
Robotic -Guided Transversus Abdominus Plane (RTAP) BlockVAS in Obese PatientsBMI <303.00 score on a scaleStandard Deviation 2.75

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026